Full Press Release Details
Big Rock Partners Acquisition Corp. Announces Effectiveness of
Registration Statement; Confirms Annual Meeting Date of
May 24, 2021 to Approve Proposed Merger with
Big Rock Partners Recommends All Stockholders Vote
FOR ALL Proposals at Annual
NEW YORK, May 21, 2021 Big Rock Partners
Acquisition Corp. ( Big Rock or BRPA )
(Nasdaq: BRPA), a publicly traded special purpose acquisition
company, today confirmed that its Annual Meeting of Stockholders
(the Annual Meeting ) to consider the previously
announced merger agreement with NeuroRx, Inc.
( NeuroRx or the Company ) will take
place on May 24, 2021. Stockholders of record as of
April 23, 2021 (the Record Date ) are eligible to
vote at the Annual Meeting.
Rock also announced that the U.S. Securities and Exchange
Commission has declared effective its registration statement on
Form S-4 (as amended, the Registration
Statement ), which includes a definitive proxy
statement/prospectus to be used in connection with the Annual
Meeting. The Registration Statement is available on the SEC's
website at www.sec.gov, and is being
mailed to stockholders of record.
Rock recommends all stockholders vote FOR ALL
PROPOSALS in advance of the Annual Meeting by telephone, via the
Internet or by signing, dating and returning the proxy card upon
receipt by following the easy instructions on the proxy
Rock also announced that it is extending the time period for
holders of shares of common stock issued in BRPA's initial
public offering ( Public Shares ) to demand conversion
rights. If you are a holder of Public Shares and wish to exercise
your conversion rights, you must demand that BRPA convert your
shares to cash and deliver your shares to BRPA's transfer
agent physically or electronically using Depository Trust
Company's DWAC (Deposit Withdrawal at Custodian) System no
later than ten business days after the vote at the meeting. Any
holder of Public Shares who holds Public Shares immediately prior
to the completion of the business combination with NeuroRx will be
entitled to demand that his, her, or its shares be converted for a
full pro rata portion of the amount then in the trust account
(which was approximately $6.0 million, or approximately $10.80 per
share, as of April 23, 2021, the record date), regardless of
whether such holder votes in connection with the business
combination proposal or is a holder of record on the record date.
Only holders of Public Shares who hold Public Shares immediately
prior to the completion of the business combination may exercise
conversion rights over such shares.
Your Vote FOR ALL Proposals Is Important, No Matter How Many or How
draws upon more than 100 years of collective drug development
experience from senior executives of AstraZeneca, Eli Lilly,
Novartis, Pfizer, and PPD. In addition to its work on Aviptadil,
NeuroRx has been awarded Breakthrough Therapy Designation and a
Special Protocol Agreement to develop NRX-101 in suicidal bipolar
depression and is currently in Phase 3 trials. Its executive team
is led by Prof. Jonathan C. Javitt, MD, MPH, who has served as
a health advisor to four Presidential administrations and worked on
paradigm-changing drug development projects for Merck, Allergan,
Pharmacia, Pfizer, Novartis, and Mannkind, together
with Robert Besthof, MIM, who served as the Global Vice
President (Commercial) for Pfizer's Neuroscience and Pain
Division. NeuroRx recently announced a plan to complete a
business combination with Big Rock Partners Acquisition Corp
(NASDAQ:BRPA) ("BRPA"), and intends to apply for listing on the
NASDAQ under the proposed symbol "NRXP".
About Big Rock Partners Acquisition Corp.
Rock Partners is a blank check company formed for the purpose of
entering into a merger, stock exchange, asset acquisition, stock
purchase, recapitalization, reorganization, or other similar
business combination with one or more businesses or entities. Big
Rock Partners' management team includes Richard Ackerman, Chairman,
President, and Chief Executive Officer, and Bennett Kim, Chief
Financial Officer, Chief Investment Officer, Corporate Secretary
and Director. Big Rock's securities are quoted on the Nasdaq
Stock Exchange under the ticker symbols NASDAQ: BRPA, BRPAU, BRPAR
Cautionary Note Regarding Forward Looking Statements
contained in this press release that are not historical facts may
be forward-looking statements within the meaning of Section 27A of
the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934. Forward-looking statements generally relate
to future events or NeuroRx's future financial or operating
performance. In some cases, you can identify forward-looking
statements because they contain words such as "may," "will,"
"should," "expects," "plans," "anticipates," "could," "intends,"
"target," "projects," "contemplates," "believes," "estimates,"
"predicts," "potential" or "continue" or the negative of these
words or other similar terms or expressions that concern NeuroRx's
expectations, strategy, plans or intentions. Such forward-looking
statements may relate to, among other things, the outcome of any
discussions or applications for the future use of ZYESAMI, the
approvals, timing, and ability to complete the proposed business
combination with BRPA, and the combined company's ability to
continue listing on Nasdaq after closing the proposed business
combination. Such forward-looking statements do not constitute
guarantees of future performance and are subject to a variety of
risks and uncertainties. NeuroRx does not undertake any obligation
to update forward-looking statements as a result of new
information, future events or developments or
Additional Information and Where to Find It
press release relates to a proposed business combination and
related transactions (the "Transactions") between NeuroRx and BRPA.